| Symbol | IPSEF |
|---|---|
| Name | IPSEN S.A. |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 92650 France 65 Quai George Corse |
| Telephone | 331-1-44-30-43-43 |
| Fax | — |
| — | |
| Website | http://www.ipsen.com/en |
| Incorporation | FR |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Euronext Paris |
| CIK | 0001356726 |
| Description | Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding 1.2 billion in 2012. Ipsens ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2012, R&D expenditure totaled close to 250 million, representing more than 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees. Additional info from OTC: |
No news found.